Amendment No. 1 to Manufacturing Services Agreement relating to rhThrombinServices Agreement • February 29th, 2008 • Zymogenetics Inc • Biological products, (no disgnostic substances)
This Amendment No. 1 to Manufacturing Services Agreement relating to rhThrombin, dated as of December 3, 2007 (“Effective Date”), is entered into by and between Patheon Italia S.p.A. (“Patheon”) and ZymoGenetics, Inc., a Washington corporation (“ZGEN”).
AMENDMENT NO. 1 TO LICENSE AGREEMENT FOR RECOMBINANT FACTOR XIIIZymogenetics Inc • February 29th, 2008 • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 TO LICENSE AGREEMENT FOR RECOMBINANT FACTOR XIII (“Amendment No. 1”) is entered into as of December 7, 2007 (“Effective Date”) by and among ZymoGenetics, Inc., a Washington corporation whose address is 1201 Eastlake Ave. East, Seattle, WA 98102 (“ZGEN”), Novo Nordisk A/S, a Danish corporation whose address is Novo Allé, DK-2880, Bagsvaerd, Denmark (“Novo”), and Novo Nordisk Health Care AG, a Swiss corporation and wholly-owned affiliate of Novo whose address is Andreasstrasse 15, 8050 Zürich, Switzerland (“NN”). ZGEN and NN are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
